Mostrar el registro sencillo del ítem

dc.contributor.authorGenescà, E
dc.contributor.authorLazarenkov, A
dc.contributor.authorMorgades, M
dc.contributor.authorBerbis, G
dc.contributor.authorRuiz-Xivillé, Neus
dc.contributor.authorGómez-Marzo, P
dc.contributor.authorRibera, J
dc.contributor.authorJuncà, J
dc.contributor.authorGonzález-Pérez, A
dc.contributor.authorMercadal, S
dc.contributor.authorGuardia, R
dc.contributor.authorArtola, M T
dc.contributor.authorMoreno, M J
dc.contributor.authorMartinez Lopez, Joaquin 
dc.contributor.authorZamora, L
dc.contributor.authorBarba, P
dc.contributor.authorGil, C
dc.contributor.authorTormo, M
dc.contributor.authorCladera, A
dc.contributor.authorNovo, A
dc.contributor.authorPratcorona, M
dc.contributor.authorNomdedeu, J
dc.contributor.authorGonzález-Campos, J
dc.contributor.authorAlmeida, M
dc.contributor.authorCervera, J
dc.contributor.authorMontesinos, P
dc.contributor.authorBatlle, M
dc.contributor.authorVives, S
dc.contributor.authorEsteve, J
dc.contributor.authorFeliu, E
dc.contributor.authorSolé, F
dc.contributor.authorOrfao, A
dc.contributor.authorRibera, J M
dc.date.accessioned2018-11-14T12:31:59Z
dc.date.available2018-11-14T12:31:59Z
dc.date.issued2018-07-24
dc.identifier.citationJ Hematol Oncol. 2018; 11 (11) : 96.es_ES
dc.identifier.issn1756-8722es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6591
dc.description.abstractRecurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.es_ES
dc.description.sponsorshipWe would like to thank Ernest Terribes for his advice and help in qPCR design andanalysisaswellasAlbaGarcíaandJes ús-María Hernández-Rivas for providing some DNA samples. We are grateful to Isabel Granada for her helpful advice regarding cytogenetic and FISH analyses. This project was supported by the Asociación Española C ontra el Cáncer, AECC (project ref.: GC16173697BIGA), by CERCA Program/Generalitat de Catalunya, the Catalan Government: 2014-SGR225 (GRE), Obra Social “ La Caixa ” and by Celgene Spain. E. Genescà is the recipient of agrant from the Spanish Health Ministry (ISCIII, CA12/00468) and an unrestricted grant from Gilead.A. Gonzalez-Perez is supported by a Ramon y Cajal fellowship (RYC-2013-14554) of the Educational Ministry (Madrid, Spain). This work was also partially supported by FEDER funds from the ISCIII (PT13/0010/0026, CIBERONC (CB16/12/00284 and CB16/12/00400), Madrid, Spain).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCDKN2A/ARFes_ES
dc.subjectCDKN2Bes_ES
dc.subjectMRDes_ES
dc.subjectPrognosises_ES
dc.subjectT-ALLes_ES
dc.titleFrequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemiaes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30041662es_ES
dc.format.volume11es_ES
dc.format.number1es_ES
dc.format.page96es_ES
dc.identifier.doi10.1186/s13045-018-0639-8es_ES
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderGovernment of Catalonia (España) 
dc.contributor.funderFundación La Caixa 
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewed
dc.identifier.e-issn1756-8722es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13045-018-0639-8.es_ES
dc.identifier.journalJournal of hematology & oncologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Tumores Hematológicos H12O-CNIOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GC16173697BIGAes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/2014-SGR225es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CA12/00468es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RYC-2013-14554es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PT13/0010/0026es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CB16/12/00284es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CB16/12/00400es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional